Results 1 to 10 of about 288,286 (208)

Mitochondrial respiration--an important therapeutic target in melanoma. [PDF]

PLoS ONE, 2012
The importance of mitochondria as oxygen sensors as well as producers of ATP and reactive oxygen species (ROS) has recently become a focal point of cancer research. However, in the case of melanoma, little information is available to what extent cellular
Michelle Barbi de Moura, Garret Vincent, Shelley L Fayewicz, Nicholas W Bateman, Brian L Hood, Mai Sun, Joseph Suhan, Stefan Duensing, Yan Yin, Cindy Sander, John M Kirkwood, Dorothea Becker, Thomas P Conrads, Bennett Van Houten, Stergios J Moschos   +14 more
doaj   +12 more sources

Current Treatment Paradigms for Advanced Melanoma with Brain Metastases. [PDF]

Int J Mol Sci
Bonzano E, Barruscotti S, Chiellino S, Montagna B, Bonzano C, Imarisio I, Colombo S, Guerrini F, Saddi J, La Mattina S, Tomasini CF, Spena G, Pedrazzoli P, Lancia A.   +13 more
europepmc   +3 more sources

More than Just Skin-Deep: A Review of Imaging’s Role in Guiding CAR T-Cell Therapy for Advanced Melanoma

Diagnostics, 2023
Advanced melanoma is one of the deadliest cancers, owing to its invasiveness and its propensity to develop resistance to therapy. Surgery remains the first-line treatment for early-stage tumors but is often not an option for advanced-stage melanoma ...
Conor M. Prendergast, Kathleen M. Capaccione, Egesta Lopci, Jeeban P. Das, Alexander N. Shoushtari, Randy Yeh, Daniel Amin, Laurent Dercle, Dorine De Jong   +8 more
doaj   +1 more source

Treatment of Advanced Melanoma: Past, Present and Future

Life, 2020
Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons.
Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Yusuke Muto, Setsuya Aiba   +4 more
doaj   +1 more source

Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis

Frontiers in Oncology, 2022
Multiple treatments of unresectable advanced or metastatic melanoma have been licensed in the adjuvant setting, causing tremendous interest in developing neoadjuvant strategies for melanoma.
Mingyi Jing, Mingyi Jing, Yi Cai, Jing Shi, Xufan Zhang, Baohua Zhu, Baohua Zhu, Fan Yuan, Fan Yuan, Jie Zhang, Jie Zhang, Min Xiao, Mingling Chen   +12 more
doaj   +1 more source

Biology of advanced uveal melanoma and next steps for clinical therapeutics [PDF]

, 2014
Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes.
Bastian, BC, Bowcock, AM, Carvajal, RD, Flaherty, KT, Gershenwald, JE, Gutkind, JS, Luke, JJ, McKenna, KC, Patel, PM, Sato, T, Selig, S, Sossman, JA, Streicher, HZ, Sznol, M, Thurin, M, Triozzi, PL, Van Meir, EG, Welch, J   +17 more
core   +4 more sources

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma

Journal of Ophthalmic & Vision Research, 2022
The management of conjunctival melanoma is challenging due to the more frequent local recurrence and metastasis compared to other conjunctival neoplasms.
Ho-Seok Sa, Claire Daniel, Bita Esmaeli
doaj   +1 more source

OUR EXPERIENCE WITH DACARBAZINE IN THE TREATMENT OF PATIENTS WITH INOPERABLE SKIN MELANOMA [PDF]

Journal of IMAB, 2016
Objective: The standard treatment for inoperable skin melanoma is chemotherapy. The aim of this study was to explore the efficacy and safety of therapy with dacarbazine in patients with advanced melanoma.
Deyan Davidov
doaj   +1 more source

Emerging targeted therapies for melanoma treatment (Review) [PDF]

, 2014
Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease. The identification of several key molecular pathways implicated in the pathogenesis of melanoma has led to the development of novel therapies for this ...
Agarwala, Akinleye, ANGELA RUSSO, ANTONIO BIONDI, Antony, Aplin, Ascierto, Ascierto, Ascierto, Awada, BARTOLOMEA FICILI, Bataille, Bollag, Brana, Britten, Byron, Candido, Catalanotti, Chakraborty, Chang, Chapman, Chen, Chmielowski, CLAUDIO GUARNERI, Comin-Anduix, Corcoran, Curti, Davar, Davies, DEMETRIOS A. SPANDIDOS, Di Giacomo, Donia, Eisen, Eisen, Emery, Falchook, Falchook, Fellner, Feng, Flaherty, Flaherty, FRANCA MARIA PEZZINO, Garnett, Gilmartin, Gray-Schopfer, Greger, Hafsi, Hauschild, Hodi, Hodis, Hwu, Ikenoue, Infante, Isakoff, JAMES A. McCUBREY, Jang, Janku, Jessen, Johnson, Joseph, Karasarides, Kim, Kirkwood, Klinac, Levings, Libra, Ligresti, Lipkin, Lipson, Liu, Lo, Long, Mansh, Markman, MASSIMO LIBRA, McCubrey, McCubrey, McCubrey, Meier, Melero, Melero, Mendoza, Mijatovic, Oberholzer, Ogita, Pecuchet, Robert, Robert, Russo, SALVATORE TRAVALI, SAVERIO CANDIDO, Shahabi, Shao, Sondak, Sosman, Stahl, Strumberg, Strumberg, Su, Thomas, Thomas, Thompson, Tjin, Topalian, Trefzer, Trunzer, Tsai, Venesio, Villanueva, Viola, Vredeveld, Wargo, Weber, Wilhelm, Wilhelm, Wilmott, Wolchok, Yamaguchi, Zhao, Zhao   +119 more
core   +4 more sources

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain

Translational Oncology, 2020
Real-world data on BRAF mutation frequency in advanced melanoma are lacking in Spain. Moreover, data available on clinicopathological profile of patients with advanced BRAF-mutant melanoma are currently limited.
Jose A. Lopez-Martin, Ana Arance Fernández, Juan José Ríos-Martín, Javier Hernández-Losa, Lucía Alós Hernández, Pablo Cerezuela Fuentes, Sebastián Ortiz Reina, Eugenia Ortega Izquierdo, Rosa M Martí, Jesús Soberino García, Berta Ferrer Fábrega, José Luis Rodríguez Peralto   +11 more
doaj   +1 more source